Novel VSV-Based Vaccine Platform for Zika Virus

There is currently no vaccine available for protecting against Zika virus (ZIKV) infection and disease. Researchers at Nationwide Children’s Hospital and The Ohio State University have developed novel candidate ZIKV vaccines that use vesicular stomatitis virus to express ZIKV proteins. The protection conferred by our vaccines does not rely on antibodies against the ZIKV envelope protein, eliminating the potential problem of antibody dependent enhancement of other species of flavivirus. Our candidate vaccines are highly attenuated while still inducing a protective immune response against ZIKV infection.

Patents

Patent # Title Country
11,739,348 Recombinant Vectors Encoding Zika Virus Protein Subunits United States of America

Loading icon